Skip to content

    Research Use Only

    This site is an independent educational resource for research compounds. We do not sell, distribute, or endorse human consumption of any compound. By entering, you confirm you are 21 years of age or older and agree to our Terms & Privacy Policy.

    🔬 100K+ researchers trust BodyHackGuide — Join r/BodyHackGuide
    RecoveryPreclinical

    ARA-290 Dosage Guide: Protocols, Calculator & Safety

    Everything you need to know about ARA-290 dosing — protocols, safety, and where to buy.

    Dose Range

    1 mg - 4 mg subcutaneous, 3x per week

    Dosage Calculator

    Calculate exact dosing for ARA-290.

    Dosing Protocols

    Beginner

    ARA-290 Beginner Protocol

    Who this is for: First-time ARA-290 users, typically those approaching it for a specific indication (sarcoidosis-associated small fiber neuropathy, diabetic neuropathy, chronic neuropathic pain that has failed conventional therapy, or specific anti-inflammatory contexts). This protocol is NOT appropriate for general wellness or casual use — ARA-290 is a specialized investigational compound better suited for specific medical applications.

    Important prerequisites.

    Before starting ARA-290, ensure:

    1. Specific indication in mind (not general "might help" use)
    2. Comfort with subcutaneous injection technique
    3. Reliable source with valid COA (≥98% HPLC purity, molecular weight verification)
    4. Bacteriostatic water for reconstitution
    5. Insulin syringes (29-31G)
    6. Alcohol swabs
    7. Refrigerator for storage
    8. Physician awareness if being used for medical indication

    Starting dose and schedule.

    The clinical trial dose for sarcoidosis-SFN is 4 mg subcutaneous daily. For beginners, conservative titration makes sense:

    Week 1: 2 mg SubQ daily. Half the trial dose. Assess tolerance — injection site reactions, any systemic effects, blood pressure check if baseline abnormal.

    Week 2+: 4 mg SubQ daily. Standard trial dose for established indications.

    Reconstitution approach.

    Typical starting preparation:

    • 16 mg vial reconstituted with 4 mL bacteriostatic water = 4 mg/mL
    • 4 mg dose = 1 mL = 100 units on a 1 mL insulin syringe

    Alternative for smaller dosing:

    • 16 mg vial in 8 mL bacteriostatic water = 2 mg/mL
    • 2 mg dose = 1 mL = 100 units

    Injection technique.

    1. Bring vial to room temperature (5-10 minutes from refrigerator)
    2. Swab vial septum with alcohol pad, let dry
    3. Draw correct dose into insulin syringe
    4. Choose injection site — typically abdominal subcutaneous fat (2+ inches from navel), rotating sites daily
    5. Swab injection site with alcohol
    6. Insert needle at 45° angle (or 90° for very lean users with thin SubQ tissue)
    7. Slow push of peptide
    8. Withdraw needle, gentle pressure with swab
    9. Document in log — site, dose, time, any sensations

    Site rotation.

    Rotate sites daily to avoid localized reactions and tissue accumulation:

    • Day 1: Left lower abdomen
    • Day 2: Right lower abdomen
    • Day 3: Left upper abdomen
    • Day 4: Right upper abdomen
    • Day 5: Left thigh (upper outer)
    • Day 6: Right thigh (upper outer)
    • Day 7: Return to rotation start

    What to expect.

    First week: Most users notice little to nothing systemically. Mild injection site reactions (redness, warmth) are common. This is normal.

    Weeks 1-4: Gradual improvement if ARA-290 is effective for your indication. In neuropathic pain contexts, pain scores often begin to improve around week 2-3. In sarcoidosis-SFN trials, significant improvement over placebo was seen by week 4.

    Subjective effects: ARA-290 does NOT produce acute subjective effects like stimulants or nootropics. It works through tissue-level biology that manifests gradually. Do not expect to "feel" ARA-290 the way you might feel caffeine or a GLP-1 agonist's first dose.

    What to track.

    Daily log:

    • Dose administered (mg, time, injection site)
    • Any injection site reactions
    • Relevant symptom scores for your indication:
      • For neuropathy: Pain NRS (0-10), numbness/tingling (0-10), allodynia, autonomic symptoms
      • For sarcoidosis-SFN: Can use Small Fiber Neuropathy Screening List (SFNSL)
      • For general inflammation: Relevant objective biomarkers, CRP, ESR
    • General wellness: energy, sleep, mood
    • Any unusual symptoms

    Duration of beginner protocol.

    4-6 week initial trial. This is based on clinical trial durations that showed benefit in sarcoidosis-SFN. Evaluate response at week 4:

    Clear benefit: Continue protocol. Consider transitioning to maintenance or evaluating longer-term benefit.

    Partial benefit: Continue for additional 4 weeks to see if effects continue to improve. Maximum response in trials was often at 8-12 weeks.

    No benefit at 6 weeks: Consider whether this indication is responsive. Some patients do not respond. Options include discontinuation, escalation to intermediate dose protocol (unlikely to help if no response at standard dose), or reassessment.

    Monitoring during beginner protocol.

    At baseline:

    • CBC with differential (baseline hematocrit, hemoglobin)
    • CMP (metabolic and liver function)
    • Blood pressure
    • Symptom scores for target indication
    • Relevant biomarkers (CRP, fecal calprotectin, etc.)

    At week 4-6:

    • Repeat CBC (confirm no polycythemia — very unlikely but good confirmation)
    • Blood pressure check
    • Symptom reassessment
    • Plan continuation or discontinuation

    Common beginner issues.

    Injection site reactions more prominent than expected: Usually improves with site rotation. If persistent, consider changing injection technique (slower push, different needle size) or adjusting preparation (different dilution concentration).

    No improvement in target symptoms: Some indications respond better than others. Sarcoidosis-SFN has the strongest evidence; other uses are less well-established. If no response at week 4-6 at standard dose, the compound may not be effective for your specific condition.

    Cost burden: ARA-290 is expensive. Budget for $150-400+/month for ongoing use. If cost is prohibitive, discuss with physician whether alternative strategies exist for your indication.

    Stopping or continuing beyond 6 weeks.

    Reasons to continue: Clear benefit in target symptoms, acceptable cost, stable lab parameters, no adverse events.

    Reasons to stop or reassess: No benefit after adequate trial, significant adverse events, cost burden disproportionate to benefit, lifestyle/logistical issues.

    Transition from beginner to intermediate: Most users who benefit from ARA-290 continue at the standard dose (4 mg daily) rather than escalating. Higher doses have not shown superior efficacy in trials and carry slightly higher cost without clear benefit.

    Avoid during beginner protocol.

    • Starting multiple new peptides simultaneously
    • Changing baseline medications concurrently (confounds attribution)
    • Major lifestyle changes that could independently affect symptoms
    • Using ARA-290 as a "wellness" supplement without specific indication
    • Sharing vials or injection supplies
    • Using ARA-290 of questionable origin/purity

    Storage and handling.

    Lyophilized powder: Refrigerate at 2-8°C. Protect from light. Years of stability when properly stored.

    Reconstituted solution: Refrigerate at 2-8°C. Use within 28-30 days. Do not freeze. Protect from light. Do not shake vigorously.

    Cost considerations.

    Approximate 2026 US costs:

    • 16 mg vial ARA-290: $150-300+
    • At 4 mg daily, one vial lasts 4 days = $40-80/day cost
    • Monthly cost: $1,200-2,400+
    • This is expensive. Verify sourcing, ensure clear indication.

    When to seek medical advice.

    • Significant injection site reactions persisting beyond 48 hours
    • Allergic reaction signs (hives, facial swelling, wheezing)
    • Unexpected significant changes in blood pressure
    • Any unexplained significant symptom
    • Ongoing progression of the condition being treated despite ARA-290 use
    • Any new concerning symptom during treatment

    Realistic framing.

    ARA-290 is one of the more specialized research peptides with specific clinical evidence for specific indications. For sarcoidosis-associated small fiber neuropathy, it represents a genuine therapeutic option with evidence. For diabetic neuropathy, it's a promising adjunct. For other uses, it's more speculative. The cost is high and the route is injection-only. Use it with clear indication and realistic expectations — not as a general wellness supplement.

    Standard

    ARA-290 Intermediate Protocol

    Who this is for: Users with established ARA-290 experience and documented benefit, those pursuing extended treatment courses for chronic neuropathic conditions, and users combining ARA-290 with other peptides in evidence-based stacks. At the intermediate level, the focus shifts from establishing response to optimizing sustained use and integrating with complementary therapies.

    Intermediate dosing parameters.

    ARA-290 dose-response from clinical trials has not established superior efficacy at higher doses than 4 mg SubQ daily. Therefore, the intermediate protocol is not primarily about dose escalation but about:

    1. Continued 4 mg SubQ daily dosing (standard)
    2. Integration with complementary therapies
    3. Longer treatment durations
    4. Enhanced monitoring and outcome tracking

    Some users explore modified dosing schedules:

    Alternate-day dosing: Some cost-conscious users experiment with 4 mg every other day after achieving initial response. Evidence base for this schedule is anecdotal; the clinical trial protocol was daily.

    Dose reduction for maintenance: 2 mg daily as maintenance after 8-12 weeks at 4 mg daily for patients with achieved benefit. Again, limited evidence base — trial protocols continued at full dose.

    Split dosing: 2 mg BID. No clear rationale given the short plasma half-life but stable biological effects; biological effects are thought to outlast plasma levels.

    The intermediate default remains: 4 mg SubQ daily continuous, for 3-6 months or longer based on response.

    Intermediate stacking combinations.

    Once response to ARA-290 monotherapy is characterized, complementary stacks can be considered:

    Enhanced neuropathic pain protocol:

    • ARA-290 4 mg SubQ daily
    • ALCAR 1-3 g oral daily
    • Alpha-lipoic acid 600 mg daily
    • Benfotiamine (if diabetic) 150 mg BID
    • Methyl-B12 5 mg daily
    • Vitamin D 2000-5000 IU daily
    • Standard neuropathic pain medications as prescribed

    Comprehensive recovery protocol for injury/post-surgical:

    • ARA-290 4 mg SubQ daily
    • BPC-157 500 mcg SubQ BID
    • TB-500 5 mg SubQ weekly
    • Glutathione liposomal 500 mg BID
    • Vitamin C 1-2 g daily
    • Adequate protein intake
    • Physical therapy

    Sarcoidosis comprehensive adjunct (coordinate with specialist):

    • ARA-290 4 mg SubQ daily
    • Standard sarcoidosis therapy (steroids, methotrexate, anti-TNF as prescribed)
    • Vitamin D monitoring (sarcoidosis affects vitamin D metabolism)
    • KPV 500-1000 mcg daily for additional anti-inflammatory support
    • Omega-3 EPA+DHA 2-3 g daily

    Multi-system inflammatory or autoimmune adjunct:

    • ARA-290 4 mg SubQ daily
    • KPV oral 500-1000 mcg daily
    • Thymosin Alpha-1 1.6 mg SubQ twice weekly (for immune modulation)
    • GSH/NAC antioxidant support
    • Targeted anti-inflammatory diet
    • Standard immunomodulatory therapy as prescribed

    Intermediate monitoring.

    Every 4-8 weeks during intermediate use:

    • CBC with differential (confirm stable hematocrit/hemoglobin)
    • CMP
    • Blood pressure
    • Condition-specific biomarkers (CRP, ESR, fecal calprotectin, vitamin D for sarcoidosis)
    • Symptom scales for target condition (NRS for pain, SFNSL, SF-36, etc.)

    Every 3-6 months:

    • More comprehensive panel
    • Specialized testing (intraepidermal nerve fiber density if available, autonomic function testing, etc.)
    • Imaging as appropriate (FDG-PET for sarcoidosis activity, etc.)

    Objective outcome measures when possible:

    • Skin biopsy for IENFD (intraepidermal nerve fiber density) — pre/post treatment (usually 6+ months)
    • Autonomic function tests (HRV, tilt table, sudomotor function)
    • Validated quality of life measures (SF-36, FACIT-F for fatigue)

    Adjusting the protocol based on response.

    Good response maintained: Continue standard 4 mg daily. Evaluate at 6-12 months for step-down possibilities.

    Plateau after initial response: Consider addition of complementary therapies (see stacks above). Evaluate whether current dose is sufficient or if treatment fatigue is occurring.

    Loss of response: Possible tachyphylaxis (rare in trials) or disease progression beyond treatment capacity. Consider planned 2-4 week break followed by resumption.

    Inadequate initial response: At 6-8 weeks with minimal improvement, reconsider the indication. Some patients do not respond to ARA-290 even in appropriate clinical indications. Continuing longer at standard dose rarely converts non-responders to responders.

    Extended duration considerations.

    Sarcoidosis trial durations were up to 28 days for initial benefit assessment, with some follow-up data. Longer-term use (6 months to years) is community practice, supported by the favorable safety profile in trials but not rigorously tested.

    At 6 months: Evaluate continued benefit, consider planned break or dose reduction to see if effects persist.

    At 12 months: Serious reassessment. If still benefiting, consider maintenance dose reduction (2 mg daily or every-other-day) to manage cost and limit long-term exposure.

    Extended use beyond 12 months: Enters territory where no clinical trial data exist. Proceed with enhanced monitoring and clear indication.

    Post-response management.

    If the target condition resolves or enters remission:

    • Consider step-down to lower dose (2 mg daily) for 4-8 weeks
    • Then trial off ARA-290
    • Monitor for recurrence
    • Resume if symptoms return

    Some chronic conditions (sarcoidosis-SFN, diabetic neuropathy) may require indefinite treatment for symptom control. Others may allow drug-free periods.

    Cost management at intermediate level.

    ARA-290 is expensive (the most expensive peptide in most stack scenarios). Cost management strategies:

    Alternate-day dosing after initial response: 4 mg every other day = half the cost. Evidence base is anecdotal but some users report sustained benefit.

    Lower-dose maintenance: 2 mg daily after achieving 3-6 month response at 4 mg daily. Cycling: Use ARA-290 for 3-month blocks with 1-month breaks. Monitor for symptom return.

    Accurate reconstitution and dosing: Ensure vials are not wasted. Accurate dose measurement is essential.

    Reputable sourcing: Extremely variable pricing among suppliers. Seek quality with verified COAs, not just lowest cost.

    Safety considerations at intermediate level.

    • Continued monitoring for polycythemia (unlikely based on trials but worth confirming)
    • Blood pressure monitoring
    • Watch for any immunosuppression signs (infections) in combined anti-inflammatory protocols
    • Watch for injection site complications with long-term use
    • Monitor for any delayed adverse effects not seen in short-term trials

    When to step down or discontinue.

    Clinical goals achieved: Step down to maintenance or off. No benefit after adequate trial: Discontinue. Significant adverse events: Stop immediately. Cost becoming prohibitive: Discuss with physician whether alternatives exist. Pre-surgical planning: Stop 7-14 days before elective surgery. Pregnancy or pregnancy planning: Stop before conception attempts.

    When to escalate to advanced considerations.

    The concept of "advanced" is limited for ARA-290 because trial evidence doesn't support higher doses. Escalation typically means:

    • Integration with specialized therapies (infusion therapies, complex immunomodulation)
    • Refractory cases requiring comprehensive management
    • Research protocols

    Working with clinicians.

    At the intermediate level, working with a knowledgeable physician is increasingly important:

    • Functional or integrative medicine physician familiar with peptide therapies
    • Neurologist for neuropathic indications
    • Pulmonologist/rheumatologist for sarcoidosis
    • Endocrinologist for diabetic indications

    Coordinate labs, monitoring, and clinical decision-making.

    Documentation.

    Maintain detailed records:

    • Clinical trial-style symptom scales
    • Photos (for skin/visible conditions)
    • Lab trends
    • Injection site rotation log
    • Cost tracking
    • Side effects and adverse events

    This documentation supports informed decision-making and can be shared with treating clinicians.

    Advanced

    ARA-290 Advanced Protocol

    Who this is for: Specialized cases including refractory neuropathic pain, complex sarcoidosis with severe SFN burden, combined with advanced peptide stacks for specific indications, or research-context use with clinical supervision. This protocol emphasizes that "advanced" with ARA-290 does NOT mean higher doses — the clinical trial evidence does not support dose escalation beyond 4 mg daily. Advanced use involves integration, sophistication of outcome measurement, and management of complex cases.

    Critical framing.

    ARA-290's evidence does NOT support:

    • Doses substantially above 4 mg daily
    • Different administration routes beyond SubQ (no IV, oral, intranasal, or topical protocols with evidence)
    • Use in unvalidated indications
    • Abandonment of standard therapy

    Advanced use IS about:

    • Sustained treatment courses (6+ months)
    • Comprehensive stacking for complex cases
    • Integration with research or specialty care
    • Rigorous outcome measurement

    Advanced use contexts.

    Refractory sarcoidosis-associated SFN:

    • ARA-290 4 mg SubQ daily continuous
    • Maximized standard sarcoidosis therapy (per pulmonologist/rheumatologist)
    • KPV 1000 mcg oral daily for enhanced anti-inflammatory support
    • ALCAR 2-3 g daily + alpha-lipoic acid 600 mg BID for neuropathic support
    • Glutathione support (NAC + liposomal GSH)
    • Vitamin D monitoring and supplementation with careful attention
    • Pain management specialist for neuropathic pain medications
    • Physical therapy for autonomic dysfunction support
    • Dietary optimization (anti-inflammatory pattern)
    • 6-12 month trials with comprehensive outcome measurement

    Severe diabetic peripheral neuropathy:

    • ARA-290 4 mg SubQ daily
    • ALCAR 3 g daily
    • Alpha-lipoic acid 600 mg BID
    • Benfotiamine 300 mg daily
    • Methyl-B12 5 mg daily
    • Vitamin D to optimal level
    • Comprehensive diabetes management (tight glycemic control essential)
    • Standard neuropathic pain medications
    • Glutathione/NAC support
    • Consideration of SGLT2 inhibitors, GLP-1 agonists for metabolic support
    • Coordinate with endocrinology and neurology

    Complex post-surgical or injury recovery:

    • ARA-290 4 mg SubQ daily (4-6 week course)
    • BPC-157 500 mcg SubQ BID
    • TB-500 5-10 mg SubQ weekly
    • GHK-Cu (topical for surgical scars, SubQ for systemic)
    • Thymosin Alpha-1 1.6 mg SubQ twice weekly
    • Comprehensive nutritional support
    • Physical therapy and rehabilitation
    • Monitor for adequate healing and transition to rehabilitation

    Chronic inflammatory conditions adjunct:

    • ARA-290 4 mg SubQ daily
    • KPV 1000 mcg oral daily
    • Specialized anti-inflammatory stacks
    • Gut microbiome support
    • Standard medical therapy
    • Research protocols when appropriate

    Research and trial participation.

    Many advanced uses of ARA-290 are better served through enrollment in clinical trials. Araim Pharmaceuticals continues development; academic centers run investigator-initiated trials; international trials may offer access with research protocols. Trial participation often means:

    • Access to higher-quality product
    • Proper clinical oversight
    • Standardized outcome measurement
    • Contribution to knowledge base
    • Often reduced or no cost

    For rare or refractory conditions, trial participation may be the most appropriate "advanced" use.

    Advanced monitoring.

    Comprehensive baseline:

    • Full CBC with differential
    • Comprehensive metabolic panel
    • Lipid panel
    • HbA1c (if diabetic)
    • Inflammatory markers (CRP, ESR, IL-6, TNF-alpha)
    • Condition-specific biomarkers
    • Autonomic function testing (HRV, tilt, sudomotor)
    • Quantitative sensory testing for neuropathy
    • Skin biopsy for IENFD (intraepidermal nerve fiber density)
    • Quality of life measures (SF-36, EQ-5D)
    • Pain scales (NRS, DN4, LANSS)
    • Disease-specific scales (SFNSL for SFN, FACIT-F for fatigue)

    Follow-up every 3 months:

    • Standard labs
    • Symptom scales
    • Side effect review

    Every 6 months:

    • More comprehensive biomarker panel
    • Repeat specialized testing (autonomic, IENFD if indicated)
    • Overall response assessment and plan modification

    Specialized testing consideration.

    Intraepidermal Nerve Fiber Density (IENFD): Requires skin biopsy, typically from the lower leg. Performed by pathology lab familiar with the technique. Objective measure of small fiber innervation. Clinical trials of ARA-290 have shown increased IENFD with treatment — real anatomic improvement.

    Autonomic function testing: Specialized neurology/cardiology testing. May include tilt table, heart rate variability analysis, sudomotor axon reflex testing, pupillary responses.

    Quantitative sensory testing (QST): Formal measurement of thermal, mechanical, and vibration sensation thresholds.

    Nerve conduction studies / EMG: For large fiber assessment. Often normal in SFN (which specifically involves small fibers not captured by these tests) but useful to rule out larger fiber involvement.

    Multi-compound advanced stacks.

    Comprehensive neuropathic pain / small fiber neuropathy stack:

    • ARA-290 4 mg SubQ daily
    • ALCAR 3 g oral daily
    • Alpha-lipoic acid 600 mg BID
    • Methyl-B12 5 mg daily
    • Benfotiamine 300 mg daily (if diabetic)
    • PEA (palmitoylethanolamide) 600 mg BID
    • Curcumin phytosome 1500 mg daily
    • Vitamin D to optimal level
    • Standard neuropathic pain medication per pain specialist

    Advanced recovery/regeneration stack:

    • ARA-290 4 mg SubQ daily (4-week pulse)
    • BPC-157 500-1000 mcg SubQ BID
    • TB-500 10 mg SubQ weekly
    • GHK-Cu topical + SubQ as appropriate
    • Thymosin Alpha-1 1.6 mg SubQ 2x/week
    • Growth hormone secretagogue if appropriate (CJC-1295 + Ipamorelin)
    • Comprehensive nutritional support

    Longevity/anti-inflammaging stack:

    • ARA-290 4 mg SubQ 3-4 months per year in pulses
    • Off-phase: KPV, glutathione, NAD+ precursors continuous
    • Epithalon courses 2-4x/year
    • Methylene Blue low-dose daily
    • Comprehensive metabolic/longevity monitoring

    Issues specific to advanced use.

    Long-term safety beyond trial duration. Clinical trials have been up to 6 months. Advanced use often extends to years. Safety data in this extended window are not established. Enhanced monitoring and periodic drug holidays may mitigate risk.

    Pseudo-tolerance or response drift. Occasionally users report declining response after initial benefit. True tachyphylaxis has not been documented in trials. Options: planned 2-4 week break then resume, addition of complementary therapies, reassessment of diagnosis.

    Injection site complications with prolonged use. Scarring, lipodystrophy, or chronic irritation can occur with daily SubQ injections over years. Rigorous site rotation essential. Technique optimization ongoing.

    Cost sustainability. $150-400+/month for years of use = $1800-4800+/year. Assess whether the sustained cost is justified by sustained benefit.

    Drug interaction tracking. With long-term use, medication changes become more likely. Track potential interactions, particularly with new immunomodulatory agents.

    Research/trial context.

    Advanced use often benefits from:

    • Periodic consultation with investigators familiar with ARA-290
    • Participation in observational registries if available
    • Contribution to patient-reported outcome data
    • Connection with patient community for shared experience

    Exit strategy at advanced level.

    Every advanced protocol needs clear endpoints:

    • Clinical remission or significant improvement (step down, then off)
    • Declining response (re-evaluate, consider other approaches)
    • Adverse event requiring cessation
    • Financial or logistical barriers
    • Development of contraindication (pregnancy, cancer, etc.)
    • Availability of approved alternatives

    The fundamental reality at advanced levels.

    ARA-290 is a specialized investigational compound. Its advanced use is NOT about maximizing dose or aggression — it's about appropriate matching to complex cases, sustained high-quality monitoring, and integration with comprehensive management. For most users, the beginner or intermediate protocols deliver the majority of achievable benefit. Advanced use is justified by specific severe indications, refractory cases, or specialized clinical contexts — not by general "wanting more effect."

    If your condition is not responding to standard ARA-290 dosing and stacking at intermediate level, escalating to "advanced" rarely converts non-responders to responders. The more appropriate response is reassessment of the underlying condition and consideration of alternative or adjunctive approaches.

    Commonly Stacked With

    ARA-290 stacks cleanly with most other peptides and compounds because its mechanism — innate repair receptor activation — is distinct from most other pathways. Here are the major stacking patterns that make biochemical sense.

    With BPC-157 and TB-500 for comprehensive tissue repair. Perhaps the most natural stack. All three compounds support tissue repair through different mechanisms: BPC-157 via growth hormone receptor and nitric oxide pathways; TB-500 via actin sequestration and cell migration; ARA-290 via IRR activation for anti-inflammatory and cytoprotective effects. For injuries, post-surgical recovery, or chronic tissue damage scenarios, the combination addresses different arms of the repair process. Typical stacking approach: BPC-157 500 mcg SubQ or oral BID, TB-500 2-5 mg SubQ weekly or divided, ARA-290 4 mg SubQ daily (for active treatment phase). Duration: 4-8 weeks for acute conditions, longer for chronic. No known interactions; mechanism-complementary.

    With KPV for anti-inflammatory protocols. KPV inhibits NF-kB-driven inflammation through PepT1-mediated cellular uptake. ARA-290 reduces inflammation through IRR activation with different downstream signaling (JAK2/STAT3). The combination addresses inflammation through distinct pathways — theoretically additive. Used in autoimmune adjunct protocols, chronic inflammation management, and some gastrointestinal indications. Typical addition: KPV 500-1000 mcg oral daily alongside ARA-290 4 mg SubQ daily.

    With GHK-Cu for skin, wound healing, and regenerative applications. GHK-Cu supports tissue regeneration through copper-peptide signaling and extracellular matrix effects. ARA-290 supports tissue protection through IRR activation. For skin conditions, wound healing, or cosmetic/anti-aging protocols, the combination addresses multiple regenerative pathways. Particularly useful when fibrosis prevention or controlled healing is desired. Typical use: topical GHK-Cu with systemic ARA-290.

    With thymosin alpha-1 for immune modulation. Thymosin Alpha-1 modulates immune cell function and supports innate and adaptive immunity. ARA-290 has anti-inflammatory effects and tissue protection. The combination is useful in contexts requiring immune support alongside anti-inflammatory effects — certain chronic infections, post-viral syndromes, complex inflammatory conditions.

    With glutathione/NAC for oxidative stress contexts. Glutathione and NAC support antioxidant defenses and detoxification. ARA-290 reduces inflammatory pathways that generate oxidative stress. The combination addresses oxidative stress from two angles — reducing generation (ARA-290 anti-inflammatory) and enhancing clearance (GSH). Useful in diabetic neuropathy, chemotherapy-induced neuropathy, and post-infection recovery contexts. Typical use: ARA-290 4 mg SubQ daily + liposomal GSH 500 mg BID + NAC 600 mg BID.

    With L-carnitine/ALCAR for neuropathy support. L-carnitine (particularly the ALCAR form) has strong evidence for diabetic and chemotherapy-induced neuropathy. ARA-290 also targets neuropathic pain through different mechanisms. For patients with established neuropathy, this is a mechanism-complementary stack. Typical: ALCAR 1-3 g oral daily + alpha-lipoic acid 600 mg daily + ARA-290 4 mg SubQ daily. This is a multimodal neuropathy protocol with different evidence for each component.

    With methylene blue for mitochondrial/neurological protocols. Methylene Blue supports mitochondrial function through alternative electron transport carrier effects. ARA-290 supports tissue protection through IRR activation. The combination is used in some neurological and longevity protocols for mitochondrial and cellular protection.

    With GLP-1 agonists during weight loss. ARA-290 may have some role in supporting metabolic tissue during rapid weight loss, though evidence is limited. Some community protocols combine ARA-290 with Semaglutide, Tirzepatide, or Retatrutide for comprehensive metabolic and tissue support. Evidence is mechanistic rather than clinical.

    With growth hormone secretagogues for recovery and body composition. ARA-290 does not directly affect growth hormone or IGF-1 axes. Stacking with CJC-1295, Ipamorelin, Sermorelin, or MK-677 is pharmacologically independent — different mechanisms, no conflicts. Used in athletic recovery, body composition, and general optimization protocols.

    With peripheral neuropathy standard therapy. ARA-290 can be combined with gabapentin, pregabalin, duloxetine, tricyclic antidepressants, and other standard neuropathic pain medications. Different mechanisms (ion channel modulation, monoamine reuptake inhibition vs IRR activation). Many clinical trial patients have been on these concurrent medications. Combinations should be coordinated with prescribing physician for dose adjustment as pain improves.

    With sarcoidosis immunosuppressive therapy. Many ARA-290 trial patients with sarcoidosis-SFN have been on concurrent corticosteroids, methotrexate, anti-TNF biologics, or other sarcoidosis treatments. No pharmacological interaction identified. ARA-290 addresses the neuropathic complication; standard therapy addresses the underlying disease.

    For diabetic patients — multimodal neuropathy stack.

    A comprehensive diabetic neuropathy stack might include:

    • ARA-290 4 mg SubQ daily
    • ALCAR 1-3 g daily
    • Alpha-lipoic acid 600 mg daily
    • Benfotiamine 150 mg BID
    • Methyl-B12 5 mg daily
    • Vitamin D 2000-5000 IU daily
    • Standard glycemic control optimization
    • Standard neuropathic pain medication if needed (pregabalin, duloxetine)

    Each component addresses different arms of diabetic neuropathy pathology.

    For post-surgical or injury recovery.

    A recovery-focused stack:

    • ARA-290 4 mg SubQ daily during active healing phase (2-6 weeks)
    • BPC-157 500 mcg SubQ BID
    • TB-500 5 mg SubQ weekly
    • Vitamin C 1-2 g daily
    • Zinc, copper for wound healing
    • Adequate protein intake
    • Physical therapy as appropriate

    For chronic inflammatory conditions.

    An anti-inflammatory stack:

    • ARA-290 4 mg SubQ daily
    • KPV 500-1000 mcg oral daily
    • Omega-3 EPA+DHA 3-4 g daily
    • Curcumin/turmeric high-bioavailability form 500-1000 mg daily
    • Glutathione support (NAC + liposomal GSH)
    • Dietary anti-inflammatory pattern (Mediterranean, low glycemic)

    For sarcoidosis-specific support.

    Coordinated with rheumatology/pulmonology:

    • ARA-290 4 mg SubQ daily (for SFN symptoms)
    • Standard sarcoidosis therapy (corticosteroids, methotrexate, anti-TNF as prescribed)
    • Vitamin D (careful — monitor levels; sarcoidosis can cause altered vitamin D metabolism)
    • KPV for additional anti-inflammatory support
    • Glutathione support

    Stacking caveats and cautions.

    With recombinant EPO or darbepoetin: Combined with systemic EPO therapy, the rationale for ARA-290 becomes complicated — the whole point is to avoid EPO's hematopoietic effects. No clear clinical scenario would combine them.

    With experimental immunotherapies: Theoretical caution about immune modulation effects compounding. Typically avoided.

    With high-dose corticosteroids for prolonged periods: The anti-inflammatory effects may compound. Monitor for infection risk in combined immunomodulatory regimens.

    With active chemotherapy: Oncology coordination essential. Theoretical concerns about growth factor or cytoprotective effects on tumor cells.

    Timing considerations.

    ARA-290 timing: Morning or evening both acceptable. No specific circadian rationale for timing. Consistency matters more than specific time of day.

    In relation to other peptides: Different injection sites and timing are fine. Some users prefer separate injections to avoid dose confusion.

    With meals: Subcutaneous injection is not meal-dependent. Oral peptides in the stack should follow their own meal timing guidance.

    Stack introduction discipline.

    For diagnostic clarity: introduce ARA-290 alone for 4 weeks before adding other peptides. This allows attribution of effects. If ARA-290 is the primary intervention for a specific indication (sarcoidosis-SFN, diabetic neuropathy), layer it in as the "foundation" and add supporting compounds once response is characterized.

    Cost reality for stacks.

    ARA-290 is expensive — typically $150-400+ per month depending on source and dosing. Combined with other peptides (BPC-157, TB-500, KPV), monthly costs can be $300-800+. Advanced comprehensive stacks: $500-1500+ per month.

    Ensure cost-benefit analysis supports continued combined protocol use.

    Side Effects & Safety

    ARA-290 has demonstrated a notably favorable safety profile across clinical trials — one of the cleaner safety records among research peptides. The engineering rationale of separating tissue-protective effects from hematopoietic effects appears to have largely succeeded in clinical translation. **What has NOT been seen in clinical trials (important negatives):** *No polycythemia/erythrocytosis.* ARA-290 does not increase hematocrit, hemoglobin, or red blood cell count in trials, even with chronic daily administration at therapeutic doses. This is the primary safety concern that ARA-290 was engineered to avoid (compared to recombinant EPO), and clinical data have validated the engineering goal. *No hypertension.* Unlike recombinant EPO, which can raise blood pressure substantially (part of the hematocrit-related mechanism and direct vascular effects), ARA-290 does not affect blood pressure meaningfully in trials. *No thrombotic events.* No increased rate of deep vein thrombosis, pulmonary embolism, stroke, or myocardial infarction has been observed in trials. Given that the primary concern with non-selective EPO receptor activation is thrombosis secondary to elevated hematocrit, this absence is reassuring. *No significant cardiovascular adverse events.* No heart failure, arrhythmia, or other cardiac adverse events have been attributed to ARA-290. *No immunogenicity problems.* Despite being a peptide drug, ARA-290 has not shown significant antibody development or hypersensitivity reactions in trials over months of use. **What HAS been observed (typical mild effects):** *Injection site reactions.* The most common adverse event. Mild redness, warmth, swelling, or transient discomfort at subcutaneous injection sites. Usually resolves within hours. Rotation of injection sites minimizes frequency. More pronounced with improper injection technique. *Transient mild headache.* Occasional reports; typically mild and self-limiting. More common in first days of treatment. *Mild fatigue.* Rare reports of mild fatigue, particularly in first days of treatment. May reflect the body's metabolic response to the tissue-signaling peptide. Usually resolves within 1-2 weeks. *Gastrointestinal effects.* Occasional mild nausea or GI discomfort; uncommon. More likely reflective of individual sensitivity than direct drug effect. *Mild transient "flu-like" feeling.* Rare, typically very mild, more common in first days. Consistent with mild cytokine modulation. **Theoretical safety concerns (not confirmed in trials but mechanistically considered):** *Growth factor concerns in malignancy.* Because the IRR is involved in cell survival and anti-apoptotic signaling, there is theoretical concern about potential effects on tumor cells. This is why recombinant EPO has been studied cautiously (and sometimes with negative results) in cancer patients. ARA-290's different receptor selectivity may reduce this concern, but clinical experience in oncology populations is limited. Anyone with active malignancy should not use ARA-290 without oncology consultation. *Immune system effects.* ARA-290 has immunomodulatory properties (modulating macrophage polarization, reducing pro-inflammatory cytokines). In theory, this could affect immune surveillance or response to infection. Clinical trials have not shown increased infection rates, but the trial populations have been limited in size and duration. *Retinal considerations.* The retina expresses EPO receptors and IRR components. ARA-290 is being explored as a retinal therapeutic, which is generally beneficial. However, in theory, significant receptor modulation could affect retinal function. No adverse retinal effects have been noted in trials to date. *Renal effects.* EPO receptors and IRR components are expressed in kidney. ARA-290 appears to protect renal tissue in preclinical ischemic models. No adverse renal effects have been noted clinically. *Long-term effects on tissue regeneration.* Chronic stimulation of tissue repair pathways could theoretically have unexpected long-term consequences (fibrosis, dysregulated healing), though clinical trials have not shown this and preclinical models generally show favorable long-term effects. **Hypersensitivity and allergic reactions.** As with any injectable peptide, allergic or hypersensitivity reactions are theoretically possible: - Mild skin reactions at injection sites (common, typically self-limiting) - Urticaria/hives (rare, warrants discontinuation) - Anaphylaxis (not reported in trials but theoretically possible with any injectable biologic) - Reactions to formulation excipients (bacteriostatic water preservatives, etc.) rather than ARA-290 itself **Drug interactions.** The drug interaction profile is limited because ARA-290 is pharmacologically selective. Most common medications do not have documented interactions: *Corticosteroids:* No documented interaction. Often used concurrently in sarcoidosis patients (who may be on steroids for inflammation) without problems. *Biologics (anti-TNF, anti-IL-17):* No documented interaction. Sarcoidosis trial patients have often been on these with coadministered ARA-290. *Anticoagulants/antiplatelets:* No known interaction. ARA-290 does not affect coagulation pathways. *Neuropathic pain medications (gabapentin, pregabalin, duloxetine, tricyclic antidepressants):* No known interaction; may be additive or synergistic in neuropathic pain indications. *Opioid analgesics:* No known interaction. *Immunosuppressants (cyclosporine, tacrolimus, methotrexate):* Not specifically studied but no mechanism-based concern. Sarcoidosis patients on methotrexate have received ARA-290 in trials without problems. *Recombinant EPO:* Using ARA-290 alongside recombinant EPO has not been specifically studied and is not a typical clinical scenario. There is no clear mechanism-based concern, but coordination would be needed with a nephrologist or hematologist if both were being considered. *Chemotherapy agents:* Oncology coordination essential. Theoretical concerns about growth factor effects on tumor cells, though ARA-290's IRR selectivity is distinct from the classical EPO receptor concerns. *Other research peptides (BPC-157, TB-500, GHK-Cu, KPV, etc.):* No documented interactions. Different mechanism targets. Common in community stacks without reported problems. **Specific population considerations.** *Pregnancy:* No human data. Given the tissue-protective mechanism and lack of hematopoietic effects, theoretically lower concern than recombinant EPO, but without specific safety data, should be avoided during pregnancy. *Lactation:* No human data. Peptide would likely be degraded in breast milk/infant GI tract, but without confirmation, caution is appropriate. *Pediatrics:* No pediatric clinical trial data. Adult dosing should not be extrapolated to children. Pediatric use in the community setting is not appropriate. *Elderly:* Adult dosing generally appropriate. Elderly patients have been included in clinical trials without apparent age-specific adverse effects. *Renal impairment:* Not specifically studied. Mild to moderate CKD probably safe at standard dose. Severe CKD/dialysis: no specific data; would require clinical oversight. *Hepatic impairment:* Not specifically studied. Peptide metabolism and clearance should be minimally affected by hepatic function. Probably safe but consult physician in advanced liver disease. **Monitoring considerations during use.** *Standard labs before and periodically during treatment:* - CBC with differential (particularly hematocrit and hemoglobin to confirm absence of polycythemia — though trials have not shown this, individual patient monitoring is prudent) - Comprehensive metabolic panel (CMP) - Blood pressure monitoring (reassuring if stable) - Symptom tracking (particularly for the condition being treated) *For neuropathy indications:* - Validated pain scales (NRS, SFNSL, or condition-specific scales) - Quality of life measures (SF-36 or similar) - Neurologic examination at intervals - Consider skin biopsy for IENFD if available, at baseline and after 6 months **Red flags warranting immediate discontinuation:** - Allergic reaction signs (hives, wheezing, swelling) - Unexplained significant increase in hematocrit - Unexplained significant increase in blood pressure - New thrombotic or embolic event - Severe or progressive symptom not explained by underlying condition - Any severe adverse event requiring medical attention **Typical user experience.** Most users tolerate ARA-290 well. The most common reported experience: - Mild injection site reactions in first few days, then settling - Nothing systemically noticeable in first 1-2 weeks - Gradual improvement in target symptoms (if ARA-290 is effective for that individual) over 2-8 weeks - Sustained benefit with continued dosing - Reversible effects upon discontinuation (slow decline of benefit over weeks) **Comparison with recombinant EPO safety.** The key engineered advantage of ARA-290 over recombinant EPO is the safety profile: - EPO: Polycythemia, hypertension, thrombotic risk, potential mortality increase in non-anemia populations - ARA-290: None of these effects documented in trials to date This is the central value proposition — obtaining tissue-protective benefits without the safety concerns that led to restrictive labeling for EPO use outside classical anemia indications. **Overall safety summary.** ARA-290 has one of the cleaner safety profiles among research peptides and investigational drugs. The engineering rationale has been validated in clinical trials. That said, long-term safety data (beyond 6-12 months) are limited, and community use should consider: the compound is not FDA-approved, sourcing quality varies, and extrapolation from trial populations to community users should be done carefully. When used as community-level research peptide, standard cautions about peptide sourcing, preparation, and injection technique apply.

    Contraindications

    ARA-290's favorable safety profile in clinical trials makes for a relatively limited contraindication list, but specific cautions apply. **Absolute contraindications:** **Known hypersensitivity to ARA-290 or formulation excipients.** Prior severe allergic reaction to ARA-290 or bacteriostatic water preservatives contraindicates repeat use. **Active malignancy without oncology coordination.** Despite the different receptor selectivity compared to EPO, ARA-290 has tissue-protective and anti-apoptotic effects. In theory, this could affect tumor cell survival. Classical EPO has been restricted in oncology contexts due to concerns about potentially promoting tumor survival. Whether ARA-290's IRR selectivity eliminates this concern is not fully established. For patients with active cancer or recent (<5 year) cancer history, ARA-290 should not be used without explicit oncology clearance and coordination. **Untreated serious active infection.** ARA-290 has immunomodulatory and anti-inflammatory effects. During active sepsis, serious bacterial infection, or disseminated viral infection, blunting inflammatory response may be counterproductive. Treat infection first; consider ARA-290 after resolution. **Relative contraindications (caution required):** **Pregnancy.** No human safety data. ARA-290 should be avoided during pregnancy absent specific clinical indication and obstetrical oversight. The theoretical tissue-protective effects might be hypothetically beneficial, but without data, caution is appropriate. **Lactation.** Similar lack of data. Avoid during breastfeeding. **Active or recent (< 6 months) thrombotic event.** Though clinical trials have not shown thrombotic events with ARA-290 (unlike recombinant EPO), patients with recent DVT, PE, stroke, or MI should use ARA-290 with caution and physician oversight. **Significant cardiovascular disease.** While ARA-290 has shown cardiac-protective effects in preclinical studies, patients with unstable cardiovascular disease should coordinate use with cardiologist. **Uncontrolled hypertension.** Although ARA-290 has not shown hypertensive effects in trials (unlike recombinant EPO), patients with poorly-controlled hypertension should establish blood pressure control before initiating. **Recent surgery.** Allow wound healing to complete before starting injections. Typically 2-4 weeks post-surgery; more for major procedures. If planning elective surgery, stop ARA-290 7-14 days before procedure. **Severe kidney disease.** No specific contraindication, but pharmacokinetics not studied in advanced renal disease. Coordinate with nephrology. **Severe liver disease.** No specific contraindication, but coordinate with gastroenterology/hepatology. **Active immunosuppressive therapy.** May compound anti-inflammatory effects with potential for infection risk. Coordinate with prescribing physician. **Drug interactions:** **Recombinant EPO (epoetin, darbepoetin).** No specific clinical data on combination. Mechanistically the rationale for ARA-290 is to avoid EPO's hematopoietic effects; combining them would seem to defeat that purpose. Not a typical clinical scenario. **Corticosteroids.** Commonly used concurrently with ARA-290 in sarcoidosis trials without reported problems. No clinically significant interaction documented. Anti-inflammatory effects may be additive. **Methotrexate, cyclosporine, tacrolimus, mycophenolate.** Used concurrently in some sarcoidosis trial patients. No specific interaction reported. Theoretical concern about additive immunomodulation; monitor for infection. **Anti-TNF biologics (infliximab, adalimumab, etanercept).** Sarcoidosis trial patients have used these concurrently with ARA-290. No documented interaction. Monitor for infection as with any combined anti-inflammatory therapy. **Neuropathic pain medications (gabapentin, pregabalin, duloxetine, tricyclic antidepressants, opioid analgesics).** No known clinically significant interaction. Different mechanisms. Combination may be additive or synergistic in neuropathic pain. Standard dose management of each. **Chemotherapy.** Oncology coordination essential. Theoretical concerns about growth factor-related effects on tumor cells. **Anticoagulants, antiplatelets.** No known interaction. ARA-290 does not affect coagulation pathways meaningfully. **Antiarrhythmic drugs.** No known interaction. ARA-290 has not shown arrhythmogenic effects in trials. **Diabetes medications (insulin, metformin, sulfonylureas, GLP-1 agonists).** No known interaction. Compatible. Note that ARA-290 may improve diabetic microvascular function, which could theoretically improve glycemic control over time; monitor as usual. **Statins.** No known interaction. **Thyroid replacement.** No known interaction. **Estrogen/hormone replacement therapy.** No known interaction. **Growth hormone or GH secretagogues (CJC-1295, Ipamorelin, MK-677).** No known interaction. Compatible. **Other research peptides (BPC-157, TB-500, GHK-Cu, KPV, Thymosin Alpha-1).** Widely stacked in community. No reported significant interactions. Different mechanism targets. **Vaccines.** No specific contraindication. Standard vaccine response should be adequate. **Alcohol.** No direct interaction. Moderate alcohol consumption is not contraindicated. **Specific population considerations:** **Athletes/sports contexts.** ARA-290 is NOT prohibited by WADA or major sports authorities as a specific compound as of early 2026, but EPO-related compounds have historically faced scrutiny. Athletes in tested sports should verify current regulatory status. Given the anti-inflammatory and recovery-related effects, therapeutic use should be documented carefully. **Elderly.** Adult dosing generally appropriate. Monitor for drug interactions (more common with polypharmacy). Specific geriatric data limited but extrapolation from trial populations (which have included older adults) is reasonable. **Pediatric.** No pediatric data. Inappropriate for community use in children. **Sickle cell disease.** No specific data. The distinct receptor mechanism suggests no exacerbation of sickling, but clinical experience is absent. Coordinate with hematology. **Polycythemia vera or secondary polycythemia.** Reassuringly, ARA-290 does not stimulate erythropoiesis. Patients with these conditions should theoretically be safe, but coordinate with hematology to monitor hematocrit during treatment. **Inherited prothrombotic disorders (Factor V Leiden, prothrombin mutation, etc.).** Not specifically studied. Standard trial populations may not have specifically included these patients. Coordinate with hematology if these conditions are present. **Genetic considerations.** *EPO receptor polymorphisms.* Some variants affect EPO responsiveness. Whether these affect ARA-290 responsiveness is less clear; the receptor selectivity of ARA-290 may reduce variability. *Beta-common receptor variants.* Potentially relevant for ARA-290 response. Not routinely tested. **Monitoring recommendations.** *Baseline:* - CBC with differential (hematocrit, hemoglobin — to confirm no polycythemia during treatment) - Comprehensive metabolic panel - Blood pressure - Condition-specific evaluation *Periodic (every 4-8 weeks during treatment):* - CBC (confirm stable hematocrit) - CMP - Blood pressure - Condition response assessment *Extended use monitoring:* - At 6 months: Expanded panel, reassessment of ongoing benefit - Annually: Comprehensive re-evaluation **Stop ARA-290 and seek medical evaluation for:** - Unexpected significant increase in hematocrit or hemoglobin - Unexpected hypertension or blood pressure instability - Signs of thrombotic event (leg pain/swelling, chest pain, shortness of breath, neurologic symptoms) - Allergic reaction signs - New infection symptoms - Any severe or progressive symptom - Pregnancy discovery - New cancer diagnosis **Not contraindications (common misconceptions):** - Mild to moderate hypertension (if controlled) - Type 2 diabetes (actually may be indication) - Stable cardiovascular disease (may be beneficial) - Previous uncomplicated surgery (after healing) - History of seasonal allergies - Normal infection history - Most standard medications **Pre-ARA-290 decision checklist.** Before starting ARA-290, confirm: 1. Specific indication with at least moderate evidence basis (sarcoidosis-SFN, diabetic neuropathy, etc.) 2. Absence of absolute contraindications 3. Awareness of relative contraindications and appropriate clinical oversight 4. Informed consent regarding investigational status 5. Reliable source with valid COA 6. Financial sustainability for treatment course 7. Logistical ability for daily injections 8. Monitoring plan in place **When to include physician oversight.** Strongly consider physician involvement if: - Any of the relative contraindications apply - On multiple medications (even if no specific documented interaction) - Advanced age or polypharmacy - Complex medical history - Specific condition with evidence base (sarcoidosis, diabetic neuropathy) — clinician familiar with condition - Using for indication outside clinical trial evidence - Intending prolonged use (6+ months) - Stacking with multiple other peptides **Final framing.** ARA-290's safety profile in clinical trials has been notably clean. Most users tolerate it well. The short list of contraindications reflects this — it's a relatively low-interaction, low-side-effect compound when used appropriately. That said, it's an investigational drug not FDA-approved for any indication, so the standard cautions about peptide sourcing, preparation, and informed consent apply to any community use.

    Check interactions with the Interaction Checker →

    Additional Notes

    ARA-290 dosing is relatively straightforward because clinical trials have focused on a specific daily SubQ dose range. Here is the practical breakdown.

    Standard dose (clinical trial established):

    • 4 mg subcutaneous daily — this is the dose used in Phase 2 trials for sarcoidosis-SFN and diabetic neuropathy
    • Duration: Continuous daily dosing; trial durations 28 days to several months

    Beginner starting dose:

    • 2 mg SubQ daily for first week (conservative titration)
    • 4 mg SubQ daily from week 2 onward

    Intermediate/standard:

    • 4 mg SubQ daily continuous

    "Advanced" (not dose-based):

    • Same 4 mg daily dose with longer durations, comprehensive monitoring, and stack integration
    • Higher doses have not shown superior efficacy in trials

    Alternative schedules (community practice; limited evidence):

    Alternate-day dosing: 4 mg SubQ every other day. Some users report sustained benefit. Reduces cost by half.

    Maintenance dose reduction: 2 mg daily as maintenance after achieving response at 4 mg daily.

    Split dosing: 2 mg BID. No clear rationale given short plasma half-life but stable biological effects.

    Pulsing: 3-month on, 1-month off cycles.

    Route: Subcutaneous only (evidence-based).

    SubQ is the only route with clinical evidence. Injection sites include abdominal SubQ fat, thigh, upper arm SubQ tissue. Rotate sites daily.

    Other routes (no evidence):

    Intranasal: Some community interest, no published efficacy data in humans. Intravenous: Not studied clinically. Oral: Not studied; peptide would be degraded in GI tract. Topical: Not studied for skin conditions; theoretical mechanism exists but no human data.

    Reconstitution dosing math.

    Standard preparation 1: 16 mg ARA-290 + 4 mL bacteriostatic water = 4 mg/mL

    • 4 mg dose = 1 mL = 100 units insulin syringe
    • 2 mg dose = 0.5 mL = 50 units

    Alternate preparation: 16 mg ARA-290 + 8 mL bacteriostatic water = 2 mg/mL

    • 2 mg dose = 1 mL = 100 units
    • 4 mg dose = 2 mL (requires splitting into two injections)

    Vial usage:

    • 16 mg vial at 4 mg daily = 4 days of treatment
    • 16 mg vial at 2 mg daily = 8 days of treatment

    Dose-response considerations.

    Based on clinical trials, no clear dose-response advantage was demonstrated above 4 mg SubQ daily. Higher doses in some early studies did not produce superior efficacy. This is consistent with receptor-mediated mechanisms where receptor saturation is achieved at lower doses.

    Bioavailability.

    • Subcutaneous: Estimated 60-80% systemic bioavailability (typical for small peptides via SubQ)
    • Intravenous: 100% (not clinically studied for ARA-290 specifically)
    • Oral: ~0% (peptide degraded in GI tract)

    Pharmacokinetics.

    • Plasma half-life: Minutes to tens of minutes
    • Biological effect duration: Hours to days (outlasts plasma presence due to receptor/signaling effects)
    • Steady-state: Achieved within 2-3 days of daily dosing
    • Clearance: Renal filtration and peptidase degradation

    Timing.

    • Time of day: Morning or evening acceptable, no strong circadian rationale
    • With meals: Not meal-dependent (SubQ route)
    • Around exercise: No specific timing advantage documented
    • With other peptides: Can be combined at same time or separately

    Pregnancy and lactation.

    No established safe doses. ARA-290 should be avoided during pregnancy and lactation without specific medical indication and physician oversight.

    Pediatric dosing.

    No pediatric dosing data. Adult dosing should not be extrapolated to children. Pediatric use inappropriate outside research contexts.

    Elderly.

    Standard adult doses. No age-specific adjustment documented. Monitor for drug interactions (more common in polypharmacy).

    Hepatic impairment.

    Not specifically studied. Pharmacokinetics minimally affected by hepatic function (peptide metabolism is primarily enzymatic/renal). Probably safe at standard dose in mild-moderate hepatic impairment.

    Renal impairment.

    Not specifically studied. Plasma clearance primarily renal. Severe CKD may require dose reduction or extended dosing intervals. Consult nephrology for advanced renal disease.

    Missed doses.

    • If <12 hours to next dose: Skip missed dose; take next scheduled dose
    • If >12 hours and <24 hours: Take missed dose, then skip one day to re-synchronize
    • Do not double-dose
    • Consistent daily dosing is ideal; occasional missed days are tolerated

    Cost per dose.

    Approximate 2026 US costs:

    • 16 mg vial: $150-300+
    • Per 4 mg dose: $40-80
    • Monthly cost at 4 mg daily: $1,200-2,400+
    • Monthly cost at 4 mg every other day: $600-1,200+

    This is among the more expensive peptide interventions. Budget carefully.

    Dose errors to avoid.

    Under-dosing from wrong reconstitution: Using 8 mL water with 16 mg vial and thinking you have 4 mg/mL (actually 2 mg/mL) — would result in half dose. Always verify calculations.

    Over-dosing from wrong syringe interpretation: Confusing 100-unit insulin syringe markings. 1 mL = 100 units on standard insulin syringe.

    Incomplete dose from loose technique: Not fully depressing plunger, leakage from needle site, partial aspiration issues.

    Inconsistent dosing: Variable days or amounts. Maintain a log for accuracy.

    What NOT to assume about ARA-290 dosing.

    • "More is better" — FALSE. No evidence above 4 mg daily.
    • "Higher doses produce faster effects" — FALSE. Onset is gradual regardless of dose.
    • "Oral dosing works" — FALSE. Peptide is degraded.
    • "Once-weekly dosing is fine" — Uncertain. Clinical trials used daily.
    • "Same dose for all conditions" — The evidence-based dose is for neuropathic pain. Other uses are speculative.

    Summary.

    The simple answer: 4 mg SubQ daily. Administered consistently. For 4-8 weeks minimum to evaluate response. Continued at this dose if responding. Expensive but well-tolerated. Dose optimization is less of a concern with ARA-290 than with many other peptides — the clinical dose is clear, the route is clear, and higher doses don't improve outcomes.

    Where to Buy ARA-290

    Compare 4 listings across 2 vendors — from $49.99

    Frequently Asked Questions

    What is the recommended ARA-290 dosage?

    The typical dose range for ARA-290 is 1 mg - 4 mg subcutaneous, 3x per week. Always start with the lowest effective dose.

    How often should I take ARA-290?

    Administration frequency depends on the specific protocol. Consult current research literature.

    Does ARA-290 need to be cycled?

    Cycling requirements depend on the protocol. Follow established research guidelines.

    What are ARA-290 side effects?

    ARA-290 has demonstrated a notably favorable safety profile across clinical trials — one of the cleaner safety records among research peptides. The engineering rationale of separating tissue-protective effects from hematopoietic effects appears to have largely succeeded in clinical translation. **What has NOT been seen in clinical trials (important negatives):** *No polycythemia/erythrocytosis.* ARA-290 does not increase hematocrit, hemoglobin, or red blood cell count in trials, even with chronic daily administration at therapeutic doses. This is the primary safety concern that ARA-290 was engineered to avoid (compared to recombinant EPO), and clinical data have validated the engineering goal. *No hypertension.* Unlike recombinant EPO, which can raise blood pressure substantially (part of the hematocrit-related mechanism and direct vascular effects), ARA-290 does not affect blood pressure meaningfully in trials. *No thrombotic events.* No increased rate of deep vein thrombosis, pulmonary embolism, stroke, or myocardial infarction has been observed in trials. Given that the primary concern with non-selective EPO receptor activation is thrombosis secondary to elevated hematocrit, this absence is reassuring. *No significant cardiovascular adverse events.* No heart failure, arrhythmia, or other cardiac adverse events have been attributed to ARA-290. *No immunogenicity problems.* Despite being a peptide drug, ARA-290 has not shown significant antibody development or hypersensitivity reactions in trials over months of use. **What HAS been observed (typical mild effects):** *Injection site reactions.* The most common adverse event. Mild redness, warmth, swelling, or transient discomfort at subcutaneous injection sites. Usually resolves within hours. Rotation of injection sites minimizes frequency. More pronounced with improper injection technique. *Transient mild headache.* Occasional reports; typically mild and self-limiting. More common in first days of treatment. *Mild fatigue.* Rare reports of mild fatigue, particularly in first days of treatment. May reflect the body's metabolic response to the tissue-signaling peptide. Usually resolves within 1-2 weeks. *Gastrointestinal effects.* Occasional mild nausea or GI discomfort; uncommon. More likely reflective of individual sensitivity than direct drug effect. *Mild transient "flu-like" feeling.* Rare, typically very mild, more common in first days. Consistent with mild cytokine modulation. **Theoretical safety concerns (not confirmed in trials but mechanistically considered):** *Growth factor concerns in malignancy.* Because the IRR is involved in cell survival and anti-apoptotic signaling, there is theoretical concern about potential effects on tumor cells. This is why recombinant EPO has been studied cautiously (and sometimes with negative results) in cancer patients. ARA-290's different receptor selectivity may reduce this concern, but clinical experience in oncology populations is limited. Anyone with active malignancy should not use ARA-290 without oncology consultation. *Immune system effects.* ARA-290 has immunomodulatory properties (modulating macrophage polarization, reducing pro-inflammatory cytokines). In theory, this could affect immune surveillance or response to infection. Clinical trials have not shown increased infection rates, but the trial populations have been limited in size and duration. *Retinal considerations.* The retina expresses EPO receptors and IRR components. ARA-290 is being explored as a retinal therapeutic, which is generally beneficial. However, in theory, significant receptor modulation could affect retinal function. No adverse retinal effects have been noted in trials to date. *Renal effects.* EPO receptors and IRR components are expressed in kidney. ARA-290 appears to protect renal tissue in preclinical ischemic models. No adverse renal effects have been noted clinically. *Long-term effects on tissue regeneration.* Chronic stimulation of tissue repair pathways could theoretically have unexpected long-term consequences (fibrosis, dysregulated healing), though clinical trials have not shown this and preclinical models generally show favorable long-term effects. **Hypersensitivity and allergic reactions.** As with any injectable peptide, allergic or hypersensitivity reactions are theoretically possible: - Mild skin reactions at injection sites (common, typically self-limiting) - Urticaria/hives (rare, warrants discontinuation) - Anaphylaxis (not reported in trials but theoretically possible with any injectable biologic) - Reactions to formulation excipients (bacteriostatic water preservatives, etc.) rather than ARA-290 itself **Drug interactions.** The drug interaction profile is limited because ARA-290 is pharmacologically selective. Most common medications do not have documented interactions: *Corticosteroids:* No documented interaction. Often used concurrently in sarcoidosis patients (who may be on steroids for inflammation) without problems. *Biologics (anti-TNF, anti-IL-17):* No documented interaction. Sarcoidosis trial patients have often been on these with coadministered ARA-290. *Anticoagulants/antiplatelets:* No known interaction. ARA-290 does not affect coagulation pathways. *Neuropathic pain medications (gabapentin, pregabalin, duloxetine, tricyclic antidepressants):* No known interaction; may be additive or synergistic in neuropathic pain indications. *Opioid analgesics:* No known interaction. *Immunosuppressants (cyclosporine, tacrolimus, methotrexate):* Not specifically studied but no mechanism-based concern. Sarcoidosis patients on methotrexate have received ARA-290 in trials without problems. *Recombinant EPO:* Using ARA-290 alongside recombinant EPO has not been specifically studied and is not a typical clinical scenario. There is no clear mechanism-based concern, but coordination would be needed with a nephrologist or hematologist if both were being considered. *Chemotherapy agents:* Oncology coordination essential. Theoretical concerns about growth factor effects on tumor cells, though ARA-290's IRR selectivity is distinct from the classical EPO receptor concerns. *Other research peptides (BPC-157, TB-500, GHK-Cu, KPV, etc.):* No documented interactions. Different mechanism targets. Common in community stacks without reported problems. **Specific population considerations.** *Pregnancy:* No human data. Given the tissue-protective mechanism and lack of hematopoietic effects, theoretically lower concern than recombinant EPO, but without specific safety data, should be avoided during pregnancy. *Lactation:* No human data. Peptide would likely be degraded in breast milk/infant GI tract, but without confirmation, caution is appropriate. *Pediatrics:* No pediatric clinical trial data. Adult dosing should not be extrapolated to children. Pediatric use in the community setting is not appropriate. *Elderly:* Adult dosing generally appropriate. Elderly patients have been included in clinical trials without apparent age-specific adverse effects. *Renal impairment:* Not specifically studied. Mild to moderate CKD probably safe at standard dose. Severe CKD/dialysis: no specific data; would require clinical oversight. *Hepatic impairment:* Not specifically studied. Peptide metabolism and clearance should be minimally affected by hepatic function. Probably safe but consult physician in advanced liver disease. **Monitoring considerations during use.** *Standard labs before and periodically during treatment:* - CBC with differential (particularly hematocrit and hemoglobin to confirm absence of polycythemia — though trials have not shown this, individual patient monitoring is prudent) - Comprehensive metabolic panel (CMP) - Blood pressure monitoring (reassuring if stable) - Symptom tracking (particularly for the condition being treated) *For neuropathy indications:* - Validated pain scales (NRS, SFNSL, or condition-specific scales) - Quality of life measures (SF-36 or similar) - Neurologic examination at intervals - Consider skin biopsy for IENFD if available, at baseline and after 6 months **Red flags warranting immediate discontinuation:** - Allergic reaction signs (hives, wheezing, swelling) - Unexplained significant increase in hematocrit - Unexplained significant increase in blood pressure - New thrombotic or embolic event - Severe or progressive symptom not explained by underlying condition - Any severe adverse event requiring medical attention **Typical user experience.** Most users tolerate ARA-290 well. The most common reported experience: - Mild injection site reactions in first few days, then settling - Nothing systemically noticeable in first 1-2 weeks - Gradual improvement in target symptoms (if ARA-290 is effective for that individual) over 2-8 weeks - Sustained benefit with continued dosing - Reversible effects upon discontinuation (slow decline of benefit over weeks) **Comparison with recombinant EPO safety.** The key engineered advantage of ARA-290 over recombinant EPO is the safety profile: - EPO: Polycythemia, hypertension, thrombotic risk, potential mortality increase in non-anemia populations - ARA-290: None of these effects documented in trials to date This is the central value proposition — obtaining tissue-protective benefits without the safety concerns that led to restrictive labeling for EPO use outside classical anemia indications. **Overall safety summary.** ARA-290 has one of the cleaner safety profiles among research peptides and investigational drugs. The engineering rationale has been validated in clinical trials. That said, long-term safety data (beyond 6-12 months) are limited, and community use should consider: the compound is not FDA-approved, sourcing quality varies, and extrapolation from trial populations to community users should be done carefully. When used as community-level research peptide, standard cautions about peptide sourcing, preparation, and injection technique apply.

    Where can I buy ARA-290?

    Compare 4 listings from 2 vendors on our price comparison page — starting from $49.99.

    Free 2026 Peptide Cheat Sheet — 50 pages, PDF

    Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.

    Download Free